All In Biotech

Drug Trial Radar · NCT02096354

A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: Oct 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

62

Actual

Start

May 2014

Primary completion

Apr 13, 2018

Study completion Oct 8, 2020

Sponsor

Lead sponsor
EpicentRx, Inc.Industry
Sponsor type
Industry
First posted
Mar 26, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This two-stage study is designed to compare the safety and activity between RRx-001 against regorafenib followed by irinotecan-based therapies in a parallel comparative study. Patients who are suffering from advanced or metastatic (meaning the disease has spread) colorectal cancer are invited to participate in this study. There will be two groups of patients (Randomized, open label study), one of these will receive RRx-001 and the other one will receive regorafenib. If patients qualify to participate in this study, they will be randomly assigned to the 'interventional arm' where patients will receive the experimental drug, RRx-001, or the 'control arm' where they will receive the current standard-of-care, Regorafenib. Patients have a 66% chance (2 out of 3) of receiving RRx-001 and a 33 % chance (1 out of 3) of receiving regorafenib. On progression in the first part of the study, provided ECOG performance status is adequate, and if clinically appropriate i.e. there are no absolute or relative contraindications in the opinion of the Investigator, all subjects will enter the second part of the study and receive irinotecan plus bevacizumab. Whether patients are given RRx-001 or regorafenib, they will also receive best supportive care, which includes treatments to help manage side effects and symptoms of cancer. This is an open label study, which means patients will know to which of these treatments, RRx-001 or regorafenib, they are assigned.

Conditions

  • Colorectal Neoplasms

Interventions

  • RRx-001Drug

  • RegorafenibDrug

  • IrinotecanDrug

    To be dosed after RRx-001 or regorafenib

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: From date of enrollment until death or censorship.

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • UCSD Moores Cancer Center

    La Jolla, California

  • Stanford University

    Stanford, California

  • Kaiser Permanete

    Honolulu, Hawaii

  • Walter Reed National Military Medical Center

    Bethesda, Maryland

  • Aquilino Cancer Center, Maryland Oncology and Hematology PA

    Rockville, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.